



Clinical trial results:

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Summary

EudraCT number	2007-002143-25
Trial protocol	GB DE
Global end of trial date	12 May 2022

Results information

Result version number	v1
This version publication date	03 May 2023
First version publication date	03 May 2023

Trial information

Trial identification

Sponsor protocol code	M06-873
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00481091
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie Deutschland GmbH & Co. KG
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United States, SL6 4UB
Public contact	Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com
Scientific contact	Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 May 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 May 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objectives of the Phase 1 portion of the study include:

- Safety assessment
- Dose limiting toxicity (DLT) determination
- Maximum tolerated dose (MTD) determination
- Recommended Phase 2 Dose (RPTD) and schedule determination
- Pharmacokinetic profile evaluation

The objectives of the Phase 2a portion of the study include:

- Safety assessment at the recommended Phase 2 dose (RPTD) and schedule determination
- Preliminary efficacy assessment including biomarker assessment
- Pharmacokinetic profile evaluation

Protection of trial subjects:

The study will be conducted in accordance with the protocol, International Conference on Harmonization (ICH) GCP guidelines, applicable regulations and guidelines governing clinical study conduct and ethical principles that have their origin in the Declaration of Helsinki.

Prior to the initiation of any screening or study-specific procedures, the investigator or his/her representative will explain the nature of the study to the subject and answer all questions regarding this study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 July 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	Australia: 28
Country: Number of subjects enrolled	United States: 22
Worldwide total number of subjects	60
EEA total number of subjects	2

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	19
From 65 to 84 years	41
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects underwent screening procedures within 14 days prior to initial study drug administration (Lead-in Day 1/Cycle 1 Day 1). Adult male and female subjects with chronic lymphocytic leukemia (CLL) who met the inclusion criteria and who did not meet any of the exclusion criteria were eligible for enrollment into the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Navitoclax 14/21 Day Cycle: 10 mg
------------------	-----------------------------------

Arm description:

Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 14/21 Day Cycle: 110 mg
------------------	------------------------------------

Arm description:

Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 14/21 Day Cycle: 200 mg
------------------	------------------------------------

Arm description:

Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 14/21 Day Cycle: 250 mg
------------------	------------------------------------

Arm description:

Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 21/21 Day Cycle: 125 mg
------------------	------------------------------------

Arm description:

Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 21/21 Day Cycle: 200 mg
------------------	------------------------------------

Arm description:

Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 21/21 Day Cycle: 250 mg
------------------	------------------------------------

Arm description:

Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Navitoclax 21/21 Day Cycle: 300 mg
------------------	------------------------------------

Arm description:

Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Phase 2: Navitoclax 100 mg
------------------	----------------------------

Arm description:

Navitoclax 100 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Arm title	Phase 2: Navitoclax 250 mg
------------------	----------------------------

Arm description:

Navitoclax 250 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).

Arm type	Experimental
Investigational medicinal product name	Navitoclax
Investigational medicinal product code	ABT-263
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects were instructed to self-administer navitoclax orally once daily (QD) within 30 minutes after the completion of breakfast.

Number of subjects in period 1	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg
Started	3	6	3
Completed	0	0	0
Not completed	3	6	3
Consent withdrawn by subject	-	1	1
Progressive disease other	1	1	-
Other, not specified	-	1	1
Adverse event	1	2	-
Progressive disease clinical	-	-	-
Progressive disease clinical National Cancer Inst.	1	1	-
No reason given	-	-	1

Number of subjects in period 1	Navitoclax 14/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg
Started	3	3	4
Completed	0	0	0
Not completed	3	3	4
Consent withdrawn by subject	-	-	-
Progressive disease other	1	1	1
Other, not specified	-	-	1
Adverse event	1	1	1
Progressive disease clinical	-	-	-
Progressive disease clinical National Cancer Inst.	-	-	1
No reason given	1	1	-

Number of subjects in period 1	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg	Phase 2: Navitoclax 100 mg
Started	3	4	4
Completed	0	0	0
Not completed	3	4	4
Consent withdrawn by subject	-	-	1
Progressive disease other	-	2	-
Other, not specified	-	-	-
Adverse event	2	1	1
Progressive disease clinical	-	-	1
Progressive disease clinical National Cancer Inst.	-	-	-
No reason given	1	1	1

Number of subjects in period 1	Phase 2: Navitoclax 250 mg
Started	27
Completed	0
Not completed	27

Consent withdrawn by subject	6
Progressive disease other	-
Other, not specified	4
Adverse event	6
Progressive disease clinical	7
Progressive disease clinical National Cancer Inst.	-
No reason given	4

Baseline characteristics

Reporting groups

Reporting group title	Navitoclax 14/21 Day Cycle: 10 mg
Reporting group description: Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 14/21 Day Cycle: 110 mg
Reporting group description: Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 14/21 Day Cycle: 200 mg
Reporting group description: Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 14/21 Day Cycle: 250 mg
Reporting group description: Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 125 mg
Reporting group description: Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 200 mg
Reporting group description: Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 250 mg
Reporting group description: Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 300 mg
Reporting group description: Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Phase 2: Navitoclax 100 mg
Reporting group description: Navitoclax 100 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).	
Reporting group title	Phase 2: Navitoclax 250 mg
Reporting group description: Navitoclax 250 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).	

Reporting group values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg
Number of subjects	3	6	3
Age categorical			
Units: Subjects			
< 65 years	1	0	1
>= 65 years	2	6	2
Gender categorical			
Units: Subjects			
Female	2	1	0
Male	1	5	3

Race			
Units: Subjects			
White	3	6	2
Black	0	0	0
American Indian/Alaska Native	0	0	0
Native Hawaiian or Pacific Islander	0	0	0
Asian	0	0	0
Mixed	0	0	0
Other	0	0	1
Missing	0	0	0
Ethnicity			
Units: Subjects			
Hispanic	0	0	0
No Ethnicity	3	6	3

Reporting group values	Navitoclax 14/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg
Number of subjects	3	3	4
Age categorical			
Units: Subjects			
< 65 years	1	1	3
>= 65 years	2	2	1
Gender categorical			
Units: Subjects			
Female	1	2	1
Male	2	1	3
Race			
Units: Subjects			
White	3	2	3
Black	0	0	0
American Indian/Alaska Native	0	0	0
Native Hawaiian or Pacific Islander	0	0	0
Asian	0	0	0
Mixed	0	0	1
Other	0	1	0
Missing	0	0	0
Ethnicity			
Units: Subjects			
Hispanic	0	0	0
No Ethnicity	3	3	4

Reporting group values	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg	Phase 2: Navitoclax 100 mg
Number of subjects	3	4	4
Age categorical			
Units: Subjects			
< 65 years	0	1	1
>= 65 years	3	3	3
Gender categorical			
Units: Subjects			
Female	0	3	0
Male	3	1	4

Race			
Units: Subjects			
White	2	3	4
Black	0	0	0
American Indian/Alaska Native	0	0	0
Native Hawaiian or Pacific Islander	0	0	0
Asian	0	0	0
Mixed	0	0	0
Other	1	1	0
Missing	0	0	0
Ethnicity			
Units: Subjects			
Hispanic	0	0	0
No Ethnicity	3	4	4

Reporting group values	Phase 2: Navitoclax 250 mg	Total	
Number of subjects	27	60	
Age categorical			
Units: Subjects			
< 65 years	10	19	
>= 65 years	17	41	
Gender categorical			
Units: Subjects			
Female	8	18	
Male	19	42	
Race			
Units: Subjects			
White	24	52	
Black	1	1	
American Indian/Alaska Native	0	0	
Native Hawaiian or Pacific Islander	0	0	
Asian	1	1	
Mixed	0	1	
Other	1	5	
Missing	0	0	
Ethnicity			
Units: Subjects			
Hispanic	0	0	
No Ethnicity	27	60	

End points

End points reporting groups

Reporting group title	Navitoclax 14/21 Day Cycle: 10 mg
Reporting group description: Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 14/21 Day Cycle: 110 mg
Reporting group description: Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 14/21 Day Cycle: 200 mg
Reporting group description: Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 14/21 Day Cycle: 250 mg
Reporting group description: Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 125 mg
Reporting group description: Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 200 mg
Reporting group description: Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 250 mg
Reporting group description: Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Navitoclax 21/21 Day Cycle: 300 mg
Reporting group description: Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.	
Reporting group title	Phase 2: Navitoclax 100 mg
Reporting group description: Navitoclax 100 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).	
Reporting group title	Phase 2: Navitoclax 250 mg
Reporting group description: Navitoclax 250 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).	
Subject analysis set title	Participants Receiving 14/21-Day Dosing Schedule in Phase 1
Subject analysis set type	Intention-to-treat
Subject analysis set description: Navitoclax 10, 110, 200, or 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.	
Subject analysis set title	Participants Receiving 21/21-Day Dosing Schedule in Phase 1
Subject analysis set type	Intention-to-treat
Subject analysis set description: Navitoclax 125, 200, 250, or 300 mg administered for 21 consecutive days to complete a 21-day cycle.	
Subject analysis set title	Participants Receiving Navitoclax QD Dosing in Phase 2
Subject analysis set type	Intention-to-treat
Subject analysis set description: Navitoclax 100 mg or 250 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).	

Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)

End point title	Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) ^{[1][2]}
-----------------	---

End point description:

An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An SAE is one that: results in death, hospitalization, prolongation of hospitalization, or persistent or significant disability/incapacity; is life-threatening, a congenital anomaly, or other important medical event. Events were graded as 1=mild, 2=moderate, 3=severe, 4=life-threatening, or 5=death. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A treatment-emergent adverse event is defined as any adverse event with onset or worsening reported by a subject from the time that the first dose of study drug is administered until 30 days have elapsed following discontinuation of study drug administration. Deaths category included non treatment emergent deaths.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug to 30 days post-last dose. Participants enrolled in the 14/21-day cycle received a mean of 21.7 treatment cycles; participants enrolled in the 21/21-day cycle received a mean of 19.4 treatment cycles.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics are presented per protocol.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	3
Units: participants				
Any AE	3	6	3	3
Any AE at least possibly related to navitoclax	3	4	3	3
Any AE with NCI CTCAE Grade ≥ 3	2	4	3	2
Any AE with NCI CTCAE Grade 3 or 4	2	4	3	2
Any SAE	2	4	2	2
Any AE leading to navitoclax discontinuation	1	2	0	1
Any AE leading to navitoclax dose reduction	0	1	1	2
Any AE leading to navitoclax interruption	0	4	3	2
Any AE leading to dose delay	2	3	1	2
Any DLT	0	2	0	2
Any fatal AE	0	1	0	0
Deaths	0	1	0	0

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
------------------	--	--	--	--

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	3	4
Units: participants				
Any AE	3	4	3	4
Any AE at least possibly related to navitoclax	3	4	3	4
Any AE with NCI CTCAE Grade ≥ 3	2	4	3	4
Any AE with NCI CTCAE Grade 3 or 4	2	4	3	4
Any SAE	2	4	2	3
Any AE leading to navitoclax discontinuation	2	1	2	1
Any AE leading to navitoclax dose reduction	0	1	2	0
Any AE leading to navitoclax interruption	1	4	3	4
Any AE leading to dose delay	0	0	0	2
Any DLT	0	2	2	2
Any fatal AE	1	0	0	0
Deaths	1	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Number of Participants with Dose Limiting Toxicity (DLT) in the Dose Escalation Phase

End point title	Phase 1: Number of Participants with Dose Limiting Toxicity (DLT) in the Dose Escalation Phase ^[3] ^[4]
-----------------	--

End point description:

DLTs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 (grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life threatening; grade 5=death). Any of the following events, considered possibly or probably related to the administration of navitoclax, were considered a DLT: Grade 4 thrombocytopenia ($< 25,000/\text{mm}^3$); platelet counts $< 25,000/\text{mm}^3$, Grade 2 or higher bleeding associated with thrombocytopenia; all other Grade 3, 4 or 5 adverse events were considered a DLT. Exceptions included: Grade 3, 4 febrile neutropenia less than 7 days; Grade 3, 4 leukopenia; Grade 3, 4 lymphopenia; Grade 3 nausea, vomiting and/or diarrhea unless unresponsive to treatment; Grade 2 toxicity that requires dose modification or delay of > 1 week.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 (Up to 21 days) plus 7 days

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics are presented per protocol.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	3
Units: participants	0	1	0	2

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	3	4
Units: participants	0	1	1	1

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Maximum Tolerated Dose (MTD) in the Dose Escalation Phase

End point title	Phase 1: Maximum Tolerated Dose (MTD) in the Dose Escalation Phase ^[5]
-----------------	---

End point description:

The MTD was defined as the dose at which 30% of participants experienced a DLT during the first cycle. DLTs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 (grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life threatening; grade 5=death). Any of the following events, considered possibly or probably related to the administration of navitoclax, were considered a DLT: Grade 4 thrombocytopenia ($< 25,000/\text{mm}^3$); platelet counts $< 25,000/\text{mm}^3$, Grade 2 or higher bleeding associated with thrombocytopenia; all other Grade 3, 4 or 5 adverse events were considered a DLT. Exceptions included: Grade 3, 4 febrile neutropenia less than 7 days; Grade 3, 4 leukopenia; Grade 3, 4 lymphopenia; Grade 3 nausea, vomiting and/or diarrhea unless unresponsive to treatment; Grade 2 toxicity that requires dose modification or delay of > 1 week.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 (Up to 21 days) plus 7 days

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

End point values	Participants Receiving 14/21-Day Dosing Schedule in Phase 1	Participants Receiving 21/21-Day Dosing Schedule in Phase 1		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	15	14		
Units: mg	200	250		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Recommended Phase 2 Dose (RPTD) Determined in the Dose Escalation Phase

End point title	Phase 1: Recommended Phase 2 Dose (RPTD) Determined in the Dose Escalation Phase ^[6]
-----------------	---

End point description:

The RPTD was determined based on observed DLTs and/or determination of the MTD in phase 1.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 (Up to 21 days) plus 7 days

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

End point values	Participants Receiving 14/21-Day Dosing Schedule in Phase 1	Participants Receiving 21/21-Day Dosing Schedule in Phase 1		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	15	14		
Units: mg	250	250		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Navitoclax

End point title	Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Navitoclax ^{[7][8]}
-----------------	---

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[9]	6 ^[10]	3 ^[11]	3 ^[12]
Units: hours				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	6.0 (± 2.0)	5.9 (± 1.6)	6.7 (± 1.2)	7.3 (± 1.2)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	4.3 (± 1.5)	3.5 (± 2.8)	6.8 (± 1.5)	5.7 (± 0.4)

Notes:

[9] - n=participants with an assessment at given time point

[10] - n=participants with an assessment at given time point

[11] - n=participants with an assessment at given time point

[12] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[13]	4 ^[14]	3 ^[15]	4 ^[16]
Units: hours				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	7.3 (± 1.2)	6.5 (± 1.0)	6.7 (± 2.3)	7.5 (± 1.0)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	5.8 (± 1.8)	6.7 (± 1.2)	6.9 (± 1.8)	7.3 (± 1.2)

Notes:

[13] - n=participants with an assessment at given time point

[14] - n=participants with an assessment at given time point

[15] - n=participants with an assessment at given time point

[16] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Maximum Observed Plasma Concentration (C_{max})

End point title	Phase 1: Maximum Observed Plasma Concentration
-----------------	--

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[19]	6 ^[20]	3 ^[21]	3 ^[22]
Units: µg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	0.25 (± 0.14)	1.19 (± 0.37)	2.60 (± 1.54)	5.19 (± 2.70)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	0.42 (± 0.17)	1.87 (± 0.71)	4.44 (± 3.59)	3.21 (± 0.12)

Notes:

[19] - n=participants with an assessment at given time point

[20] - n=participants with an assessment at given time point

[21] - n=participants with an assessment at given time point

[22] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[23]	4 ^[24]	3 ^[25]	4 ^[26]
Units: µg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	2.24 (± 0.98)	2.73 (± 0.82)	2.59 (± 1.60)	3.30 (± 1.20)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	2.68 (± 1.11)	3.46 (± 1.57)	3.74 (± 1.19)	3.11 (± 2.26)

Notes:

[23] - n=participants with an assessment at given time point

[24] - n=participants with an assessment at given time point

[25] - n=participants with an assessment at given time point

[26] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Area Under the Plasma Concentration-Time Curve From Time 0 to Hour 8 (AUC8)

End point title	Phase 1: Area Under the Plasma Concentration-Time Curve From Time 0 to Hour 8 (AUC8) ^{[27][28]}
-----------------	--

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[29]	6 ^[30]	3 ^[31]	3 ^[32]
Units: µg•hr/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 4, 3, 3, 3, 4, 3, 4	1.0 (± 0.65)	5.7 (± 2.7)	10.6 (± 4.0)	19.8 (± 14.0)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	2.2 (± 0.95)	11.1 (± 2.7)	24.2 (± 18.1)	17.8 (± 2.3)

Notes:

[29] - n=participants with an assessment at given time point

[30] - n=participants with an assessment at given time point

[31] - n=participants with an assessment at given time point

[32] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[33]	4 ^[34]	3 ^[35]	4 ^[36]
Units: µg•hr/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 4, 3, 3, 3, 4, 3, 4	12.0 (± 4.2)	12.3 (± 3.0)	12.0 (± 9.2)	14.3 (± 5.7)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	15.7 (± 6.8)	18.4 (± 8.7)	24.4 (± 5.7)	21.6 (± 15.6)

Notes:

[33] - n=participants with an assessment at given time point

[34] - n=participants with an assessment at given time point

[35] - n=participants with an assessment at given time point

[36] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Area Under the Plasma Concentration-Time Curve From Time 0 to Hour 24 (AUC24)

End point title	Phase 1: Area Under the Plasma Concentration-Time Curve From Time 0 to Hour 24 (AUC24) ^{[37][38]}
-----------------	--

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[39]	6 ^[40]	3 ^[41]	3 ^[42]
Units: µg•hr/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	2.7 (± 1.0)	15.0 (± 3.2)	34.0 (± 13.8)	67.8 (± 27.7)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	5.5 (± 2.7)	30.9 (± 7.7)	68.7 (± 42.9)	50.6 (± 0.36)

Notes:

[39] - n=participants with an assessment at given time point

[40] - n=participants with an assessment at given time point

[41] - n=participants with an assessment at given time point

[42] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[43]	4 ^[44]	3 ^[45]	4 ^[46]
Units: µg•hr/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	37.5 (± 16.0)	44.0 (± 18.7)	49.5 (± 12.3)	52.9 (± 20.1)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	43.5 (± 16.6)	56.2 (± 28.6)	72.7 (± 14.4)	64.8 (± 49.4)

Notes:

[43] - n=participants with an assessment at given time point

[44] - n=participants with an assessment at given time point

[45] - n=participants with an assessment at given time point

[46] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Cmax/Dose

End point title	Phase 1: Cmax/Dose ^[47] ^[48]
-----------------	--

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[49]	6 ^[50]	3 ^[51]	3 ^[52]
Units: ng/mL/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	24.5 (± 13.9)	10.7 (± 3.4)	13.0 (± 7.7)	20.8 (± 10.8)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	42.3 (± 16.6)	17.0 (± 6.4)	22.2 (± 17.9)	12.8 (± 0.48)

Notes:

[49] - n=participants with an assessment at given time point

[50] - n=participants with an assessment at given time point

[51] - n=participants with an assessment at given time point

[52] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[53]	4 ^[54]	3 ^[55]	4 ^[56]
Units: ng/mL/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	17.9 (± 7.9)	13.7 (± 4.1)	10.4 (± 6.4)	11.0 (± 4.0)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	21.4 (± 8.9)	17.3 (± 7.9)	15.0 (± 4.8)	10.4 (± 7.5)

Notes:

[53] - n=participants with an assessment at given time point

[54] - n=participants with an assessment at given time point

[55] - n=participants with an assessment at given time point

[56] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: AUC8/Dose

End point title	Phase 1: AUC8/Dose ^[57] ^[58]
-----------------	--

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[59]	6 ^[60]	3 ^[61]	3 ^[62]
Units: ng•hr/mL/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	99.9 (± 65.0)	52.0 (± 24.7)	53.1 (± 20.1)	79.2 (± 56.1)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	215 (± 95.1)	101 (± 24.7)	121 (± 90.4)	71.3 (± 9.1)

Notes:

[59] - n=participants with an assessment at given time point

[60] - n=participants with an assessment at given time point

[61] - n=participants with an assessment at given time point

[62] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[63]	4 ^[64]	3 ^[65]	4 ^[66]
Units: ng•hr/mL/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	95.8 (± 33.5)	61.3 (± 14.9)	47.9 (± 36.8)	47.6 (± 18.8)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	125 (± 54.1)	92.1 (± 43.3)	97.7 (± 22.6)	72.0 (± 51.9)

Notes:

[63] - n=participants with an assessment at given time point

[64] - n=participants with an assessment at given time point

[65] - n=participants with an assessment at given time point

[66] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: AUC24/Dose

End point title	Phase 1: AUC24/Dose ^[67] ^[68]
-----------------	---

End point description:

NOTE: One subject in the Navitoclax 14/21 Day Cycle: 250 mg arm dose-reduced to 200 mg on Days 4 to 14, and therefore was analyzed in the Navitoclax 14/21 Day Cycle: 200 mg arm for Cycle 1 Day 14.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Days 1 and 14: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[67] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6 ^[69]	3 ^[70]	3 ^[71]
Units: ng•hr/mL/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	268 (± 100)	136 (± 28.8)	170 (± 69.2)	271 (± 111)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	546 (± 267)	281 (± 69.9)	344 (± 215)	202 (± 1.5)

Notes:

[69] - n=participants with an assessment at given time point

[70] - n=participants with an assessment at given time point

[71] - n=participants with an assessment at given time point

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[72]	4 ^[73]	3 ^[74]	4 ^[75]
Units: ng•hr/mL/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1; n=3, 6, 3, 3, 3, 4, 3, 4	300 (± 128)	220 (± 93.6)	198 (± 49.3)	176 (± 67.0)
Cycle 1 Day 14; n=3, 3, 4, 2, 3, 3, 3, 3	348 (± 133)	281 (± 143)	291 (± 57.5)	216 (± 165)

Notes:

[72] - n=participants with an assessment at given time point

[73] - n=participants with an assessment at given time point

[74] - n=participants with an assessment at given time point

[75] - n=participants with an assessment at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Terminal Phase Elimination Rate Constant (β) for Navitoclax

End point title	Phase 1: Terminal Phase Elimination Rate Constant (β) for Navitoclax ^[76] ^[77]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[76] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[77] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	3	2	1 ^[78]
Units: 1/H				
arithmetic mean (standard deviation)	0.072 (± 0.029)	0.077 (± 0.006)	0.067 (± 0.030)	0.059 (± 99999)

Notes:

[78] - 99999=not applicable (1 participant analyzed)

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[79]	3	0 ^[80]	1 ^[81]
Units: 1/H				
arithmetic mean (standard deviation)	()	0.066 (± 0.025)	()	0.039 (± 99999)

Notes:

[79] - no participants analyzed in this arm

[80] - no participants analyzed in this arm

[81] - 99999=not applicable (1 participant analyzed)

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Terminal Phase Elimination Half-life (t_{1/2}) of Navitoclax

End point title	Phase 1: Terminal Phase Elimination Half-life (t _{1/2}) of Navitoclax ^[82] ^[83]
-----------------	---

End point description:

For t_{1/2}, the harmonic mean and psuedo-standard deviation are used.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1: pre-dose, 2, 4, 6, 8 hours post-dose

Notes:

[82] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

[83] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This analysis was for Phase 1 participants only.

End point values	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 14/21 Day Cycle: 250 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	3	2	1 ^[84]
Units: hours				
arithmetic mean (standard deviation)	9.62 (± 4.18)	8.99 (± 0.66)	10.41 (± 5.21)	11.72 (± 99999)

Notes:

[84] - 99999=not applicable (1 participant analyzed)

End point values	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[85]	3	0 ^[86]	1 ^[87]
Units: hours				
arithmetic mean (standard deviation)	()	10.51 (± 4.01)	()	17.88 (± 99999)

Notes:

[85] - no participants analyzed in this arm

[86] - no participants analyzed in this arm

[87] - 99999=not applicable (1 participant analyzed)

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2: Number of Participants With TEAEs, SAEs, and Discontinuations Due to AEs

End point title	Phase 2: Number of Participants With TEAEs, SAEs, and Discontinuations Due to AEs ^[88] ^[89]
-----------------	---

End point description:

An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An SAE is one that: results in death, hospitalization, prolongation of hospitalization, or persistent or significant disability/incapacity; is life-threatening, a congenital anomaly, or other important medical event. Events were graded as 1=mild, 2=moderate, 3=severe, 4=life-threatening, or 5=death. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A treatment-emergent adverse event is defined as any adverse event with onset or worsening reported by a subject from the time that the first dose of study drug is administered until 30 days have elapsed following discontinuation of study drug administration. Deaths category included non treatment emergent deaths.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug to 30 days post-last dose. Participants enrolled in Phase 2 received a mean of 15.6 treatment cycles.

Notes:

[88] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics are presented per protocol.

[89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics are presented per protocol.

End point values	Phase 2: Navitoclax 100 mg	Phase 2: Navitoclax 250 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	27		
Units: participants				
Any AE	4	27		
Any AE at least possibly related to navitoclax	4	26		
Any AE with NCI CTCAE Grade ≥ 3	3	23		

Any AE with NCI CTCAE Grade 3 or 4	3	23		
Any SAE	1	12		
Any AE leading to navitoclax discontinuation	1	9		
Any AE leading to navitoclax dose reduction	1	10		
Any AE leading to navitoclax interruption	2	16		
Any AE leading to navitoclax dose delay	2	5		
Any fatal AE	0	1		
Deaths	1	8		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2: Dose-Normalized Plasma Concentrations after Navitoclax Once Daily Dosing

End point title	Phase 2: Dose-Normalized Plasma Concentrations after Navitoclax Once Daily Dosing ^[90]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1: 4-8 h postdose; Cycle 1 Day 15: predose; Cycle 3 Day 1: predose, 4-8 h postdose; Cycle 5 Day 1: predose, 4-8 h postdose; Cycle 7 Day 1: predose, 4-8 h postdose; Cycle 9 Day 1: predose, 4-8 h postdose

Notes:

[90] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned statistics are included in the data table.

End point values	Participants Receiving Navitoclax QD Dosing in Phase 2			
Subject group type	Subject analysis set			
Number of subjects analysed	31 ^[91]			
Units: (ng/mL)/mg				
arithmetic mean (standard deviation)				
Cycle 1 Day 1: 4-8 h postdose; n=25	9.49 (± 4.80)			
Cycle 1 Day 15: predose; n=22	9.64 (± 5.85)			
Cycle 3 Day 1: predose; n=20	9.84 (± 3.55)			
Cycle 3 Day 1: 4-8 h postdose; n=17	15.2 (± 8.04)			
Cycle 5 Day 1: predose; n=21	9.84 (± 4.38)			
Cycle 5 Day 1: 4-8 h postdose; n=19	15.7 (± 8.28)			
Cycle 7 Day 1: predose; n=9	10.4 (± 5.26)			
Cycle 7 Day 1: 4-8 h postdose; n=9	15.9 (± 9.14)			
Cycle 9 Day 1: predose; n=5	11.4 (± 9.68)			
Cycle 9 Day 1: 4-8 h postdose; n=4	13.5 (± 6.41)			

Notes:

[91] - n=participants with a valid assessment at given time point

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug to 30 days post-last dose. Phase 1 14/21-day cycle participants: mean of 21.7 treatment cycles. Phase 1 21/21-day cycle participants: mean of 19.4 treatment cycles. Phase 2 participants: mean of 15.6 treatment cycles.

Adverse event reporting additional description:

All Cause mortality: Median time on study: 135, 89.5, 608, 441, 299, 307, 561, 152.5, 486.5, 803 days for Ph 1 14/21 Day Cycle 10 mg, 110 mg, 200 mg, 250 mg, Ph 1 21/21 Day Cycle 125 mg, 200 mg, 250 mg, 300mg and Ph 2 100 mg, 250 mg arms, respectively.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

Reporting groups

Reporting group title	Navitoclax 14/21 Day Cycle: 110 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Reporting group title	Navitoclax 14/21 Day Cycle: 10 mg
-----------------------	-----------------------------------

Reporting group description:

Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Reporting group title	Navitoclax 14/21 Day Cycle: 250 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Reporting group title	Navitoclax 14/21 Day Cycle: 200 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.

Reporting group title	Navitoclax 21/21 Day Cycle: 125 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.

Reporting group title	Navitoclax 21/21 Day Cycle: 200 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.

Reporting group title	Navitoclax 21/21 Day Cycle: 250 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.

Reporting group title	Navitoclax 21/21 Day Cycle: 300 mg
-----------------------	------------------------------------

Reporting group description:

Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.

Reporting group title	Phase 2: Navitoclax 100 mg
-----------------------	----------------------------

Reporting group description:

Navitoclax 100 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).

Reporting group title	Phase 2: Navitoclax 250 mg
-----------------------	----------------------------

Reporting group description:

Navitoclax 250 mg in subjects with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).

Serious adverse events	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 250 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 6 (66.67%)	2 / 3 (66.67%)	2 / 3 (66.67%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLORECTAL CANCER METASTATIC			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT MELANOMA OF EYELID			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL ADENOCARCINOMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF SKIN			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUPERFICIAL SPREADING MELANOMA STAGE UNSPECIFIED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANGINA PECTORIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEURALGIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SCIATICA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

SYNCOPE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT ISCHEMIC ATTACK			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCYTOPENIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
CHOLELITHIASIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHIECTASIS			

subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY RETENTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
ABSCCESS LIMB			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
AMOEBIASIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
APPENDICITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASPERGILLUS INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BACTERAEemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHOPULMONARY ASPERGILLOSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CELLULITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA BACTERAEemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS SALMONELLA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PHARYNGITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
PNEUMONIA KLEBSIELLA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PSEUDOMONAL SEPSIS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Metabolism and nutrition disorders			
GOUT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERCALCAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	4 / 4 (100.00%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLORECTAL CANCER METASTATIC			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT MELANOMA OF EYELID			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL ADENOCARCINOMA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUPERFICIAL SPREADING MELANOMA STAGE UNSPECIFIED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANGINA PECTORIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

DIZZINESS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEURALGIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SCIATICA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT ISCHEMIC ATTACK			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCYTOPENIA			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hepatobiliary disorders			
CHOLELITHIASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHIECTASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY RETENTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
ABSCCESS LIMB			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
AMOEBIASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
APPENDICITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASPERGILLUS INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BACTERAEemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

BRONCHOPULMONARY ASPERGILLOSIS				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
CELLULITIS				
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
ESCHERICHIA BACTERAEMIA				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
ESCHERICHIA URINARY TRACT INFECTION				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
GASTROENTERITIS SALMONELLA				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
LOWER RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PHARYNGITIS				
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PNEUMONIA				
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	

PNEUMONIA KLEBSIELLA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
PSEUDOMONAL SEPSIS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
GOUT			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERCALCAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg	Phase 2: Navitoclax 100 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	3 / 4 (75.00%)	1 / 4 (25.00%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLORECTAL CANCER METASTATIC			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT MELANOMA OF EYELID			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL ADENOCARCINOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUPERFICIAL SPREADING MELANOMA STAGE UNSPECIFIED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANGINA PECTORIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEURALGIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SCIATICA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT ISCHEMIC ATTACK			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

ANAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCYTOPENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

NAUSEA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
CHOLELITHIASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHIECTASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY RETENTION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
ABSCESS LIMB			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
AMOEBIASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

APPENDICITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASPERGILLUS INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BACTERAEemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHOPULMONARY ASPERGILLOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CELLULITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA BACTERAEemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS SALMONELLA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LOWER RESPIRATORY TRACT			

INFECTION				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PHARYNGITIS				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PNEUMONIA				
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PNEUMONIA KLEBSIELLA				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
PSEUDOMONAL SEPSIS				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Metabolism and nutrition disorders				
GOUT				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
HYPERCALCAEMIA				
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	

TUMOUR LYSIS SYNDROME			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 2: Navitoclax 250 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 27 (44.44%)		
number of deaths (all causes)	8		
number of deaths resulting from adverse events	1		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHRONIC LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
COLORECTAL CANCER METASTATIC			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MALIGNANT MELANOMA OF EYELID			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RECTAL ADENOCARCINOMA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SQUAMOUS CELL CARCINOMA			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SUPERFICIAL SPREADING MELANOMA STAGE UNSPECIFIED			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANGINA PECTORIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
NEURALGIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

SCIATICA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SYNCOPE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TRANSIENT ISCHEMIC ATTACK			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
FEBRILE NEUTROPENIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
NEUTROPENIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PANCYTOPENIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration			

site conditions			
PYREXIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CONSTIPATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
NAUSEA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
RECTAL HAEMORRHAGE			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
CHOLELITHIASIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
ACUTE RESPIRATORY FAILURE			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BRONCHIECTASIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PLEURAL EFFUSION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PNEUMONITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PULMONARY EMBOLISM			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
URINARY RETENTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			

LUMBAR SPINAL STENOSIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
ABSCCESS LIMB			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
AMOEBIASIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
APPENDICITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ASPERGILLUS INFECTION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
BACTERAEEMIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
BRONCHOPULMONARY ASPERGILLOSIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
CELLULITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

ESCHERICHIA BACTERAEMIA				
subjects affected / exposed	1 / 27 (3.70%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
ESCHERICHIA URINARY TRACT INFECTION				
subjects affected / exposed	2 / 27 (7.41%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
GASTROENTERITIS SALMONELLA				
subjects affected / exposed	0 / 27 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LOWER RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 27 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PHARYNGITIS				
subjects affected / exposed	0 / 27 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA				
subjects affected / exposed	2 / 27 (7.41%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA KLEBSIELLA				
subjects affected / exposed	1 / 27 (3.70%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY				
subjects affected / exposed	0 / 27 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

PSEUDOMONAL SEPSIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
GOUT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERCALCAEMIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Navitoclax 14/21 Day Cycle: 110 mg	Navitoclax 14/21 Day Cycle: 10 mg	Navitoclax 14/21 Day Cycle: 250 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	5
COLORECTAL ADENOMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SKIN PAPILLOMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
SQUAMOUS CELL CARCINOMA OF SKIN			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HAEMATOMA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
HYPERTENSION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HYPOTENSION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
VASCULITIS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
ADVERSE DRUG REACTION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
ASTHENIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
CHEST DISCOMFORT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
CHEST PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
FATIGUE			
subjects affected / exposed	3 / 6 (50.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	7	0	2
FEELING HOT			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
GAIT DISTURBANCE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
OEDEMA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	1	1	2
PAIN			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
PYREXIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
SECRETION DISCHARGE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
VESSEL PUNCTURE SITE PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
ALLERGY TO ARTHROPOD BITE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SEASONAL ALLERGY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Reproductive system and breast disorders			
BENIGN PROSTATIC HYPERPLASIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ERECTILE DYSFUNCTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
PENILE CURVATURE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
PROSTATITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
COUGH			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	2	0	1
DYSPNOEA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	4
EPISTAXIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	5
HAEMOPTYSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HAEMOTHORAX			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
NASAL CONGESTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
PRODUCTIVE COUGH			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
PULMONARY OEDEMA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
RESPIRATORY TRACT CONGESTION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
SINUS CONGESTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SPUTUM DISCOLOURED			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
THROAT IRRITATION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
WHEEZING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
AGITATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
ANXIETY			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	3
INSOMNIA			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	2	1	1
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
BLOOD GLUCOSE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
BLOOD MAGNESIUM DECREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HAEMOGLOBIN DECREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HEART RATE IRREGULAR			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
LIPASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

WEIGHT DECREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
WEIGHT INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	2	0	2
FALL			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
LIGAMENT SPRAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
MENISCUS INJURY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
PROCEDURAL PAIN			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
SKIN ABRASION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SKIN LACERATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SUNBURN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
WOUND			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Congenital, familial and genetic disorders PHIMOSIS subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cardiac disorders ANGINA PECTORIS subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
BRADYCARDIA subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
CARDIAC FAILURE subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
VENTRICULAR EXTRASYSTOLES subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Nervous system disorders APHASIA subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
DIZZINESS subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 3 (33.33%) 1	1 / 3 (33.33%) 1
DYSGEUSIA subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
HEADACHE subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
LETHARGY subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
NEUROPATHY PERIPHERAL			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SENSORY DISTURBANCE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
TASTE DISORDER			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
LYMPHADENOPATHY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
NEUTROPENIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
THROMBOCYTOPENIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	1	0	9
Ear and labyrinth disorders			
EAR CONGESTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
EAR DISCOMFORT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
EAR PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
CONJUNCTIVAL HAEMORRHAGE			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
DACRYOSTENOSIS ACQUIRED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ECTROPION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
EYE HAEMORRHAGE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
RETINAL HAEMORRHAGE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SWELLING OF EYELID			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN			
subjects affected / exposed	1 / 6 (16.67%)	2 / 3 (66.67%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
CONSTIPATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
DENTAL CARIES			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
DIARRHOEA			
subjects affected / exposed	4 / 6 (66.67%)	1 / 3 (33.33%)	3 / 3 (100.00%)
occurrences (all)	9	2	4

DRY MOUTH			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
DYSPEPSIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
DYSPHAGIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
FLATULENCE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
FREQUENT BOWEL MOVEMENTS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
GINGIVAL BLEEDING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
MOUTH ULCERATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	3
NAUSEA			
subjects affected / exposed	3 / 6 (50.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)
occurrences (all)	3	2	2
NONINFECTIVE GINGIVITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
ORAL PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
RECTAL FISSURE			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
RECTAL POLYP			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
STOMATITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
TONGUE ULCERATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
TOOTHACHE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
VOMITING			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Hepatobiliary disorders			
HYPERBILIRUBINAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
ACTINIC KERATOSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	6
ALOPECIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
BLOOD BLISTER			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
COLD SWEAT			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
DERMATOSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
DRY SKIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
ERYTHEMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
NIGHT SWEATS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
RASH			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
RASH VESICULAR			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SKIN DISCOLOURATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SKIN LESION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
URTICARIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Renal and urinary disorders			
DYSURIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HAEMATURIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

NOCTURIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
POLLAKEURIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
RENAL CYST			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
RENAL PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
AUTOIMMUNE HYPOTHYROIDISM			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
BACK PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
BONE PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
DUPUYTREN'S CONTRACTURE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
GROIN PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
LIMB DISCOMFORT			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
MUSCULOSKELETAL DISCOMFORT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
MYALGIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
OSTEITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
OSTEOPENIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
OSTEOPOROSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Infections and infestations			
ACUTE SINUSITIS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
BRONCHITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

CELLULITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
CONJUNCTIVITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ESCHERICHIA INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
EYE INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HAEMOPHILUS INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HERPES SIMPLEX			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
HERPES ZOSTER			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
INFLUENZA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
LICE INFESTATION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
LOCALISED INFECTION			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	5
ORAL CANDIDIASIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
ORAL HERPES			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
OTITIS MEDIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
PARONYCHIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
PNEUMONIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
PNEUMONIA KLEBSIELLA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
RHINITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
RHINOVIRUS INFECTION			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
SINUSITIS			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	3 / 3 (100.00%)
occurrences (all)	1	1	3
SKIN INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
STAPHYLOCOCCAL INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
TOOTH ABSCESS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	2 / 3 (66.67%)
occurrences (all)	1	1	5
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
VASCULAR DEVICE INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
VIRAL INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL CANDIDIASIS			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
DEHYDRATION			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HYPERGLYCAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HYPERPHOSPHATAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HYPERURICAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
HYPOKALAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
HYPOMAGNESAEMIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
HYPOVOLAEMIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
VITAMIN D DEFICIENCY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Navitoclax 14/21 Day Cycle: 200 mg	Navitoclax 21/21 Day Cycle: 125 mg	Navitoclax 21/21 Day Cycle: 200 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	4 / 4 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
COLORECTAL ADENOMA			

subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
SKIN PAPILLOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
HAEMATOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPERTENSION			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
HYPOTENSION			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
VASCULITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ADVERSE DRUG REACTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ASTHENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CHEST DISCOMFORT			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
CHEST PAIN			

subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
FATIGUE			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	2 / 4 (50.00%)
occurrences (all)	4	0	3
FEELING HOT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
GAIT DISTURBANCE			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
OEDEMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	1	1	1
PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SECRETION DISCHARGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
VESSEL PUNCTURE SITE PAIN			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			

ALLERGY TO ARTHROPOD BITE subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1
SEASONAL ALLERGY subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 2	0 / 4 (0.00%) 0
Reproductive system and breast disorders			
BENIGN PROSTATIC HYPERPLASIA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
ERECTILE DYSFUNCTION subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
PENILE CURVATURE subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
PROSTATITIS subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
ASTHMA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
COUGH subjects affected / exposed occurrences (all)	2 / 3 (66.67%) 4	1 / 3 (33.33%) 1	2 / 4 (50.00%) 2
DYSPNOEA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1
EPISTAXIS subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
HAEMOPTYSIS subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
HAEMOTHORAX			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	2 / 3 (66.67%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	5	1	2
PRODUCTIVE COUGH			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
PULMONARY OEDEMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RESPIRATORY TRACT CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SINUS CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	2
SPUTUM DISCOLOURED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
THROAT IRRITATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
WHEEZING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Psychiatric disorders			
AGITATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ANXIETY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

INSOMNIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
MENTAL STATUS CHANGES			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD GLUCOSE INCREASED			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD MAGNESIUM DECREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HAEMOGLOBIN DECREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

HEART RATE IRREGULAR			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
LIPASE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
WEIGHT DECREASED			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
WEIGHT INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
FALL			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LIGAMENT SPRAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MENISCUS INJURY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PROCEDURAL PAIN			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
SKIN ABRASION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SKIN LACERATION			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
SUNBURN			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
WOUND			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Congenital, familial and genetic disorders			
PHIMOSIS			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
Cardiac disorders			
ANGINA PECTORIS			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
BRADYCARDIA			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
CARDIAC FAILURE			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
VENTRICULAR EXTRASYSTOLES			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1
Nervous system disorders			
APHASIA			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0
DIZZINESS			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 3	0 / 4 (0.00%) 0
DYSGEUSIA			
subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
HEADACHE			

subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	1	1	1
LETHARGY			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1
NEUROPATHY PERIPHERAL			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
SENSORY DISTURBANCE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TASTE DISORDER			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LYMPHADENOPATHY			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	2	1
NEUTROPENIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	4
THROMBOCYTOPENIA			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	10	0	5
Ear and labyrinth disorders			
EAR CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EAR DISCOMFORT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EAR PAIN			

subjects affected / exposed occurrences (all)	2 / 3 (66.67%) 2	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CONJUNCTIVAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DACRYOSTENOSIS ACQUIRED			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
ECTROPION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EYE HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
RETINAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SWELLING OF EYELID			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
ABDOMINAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
CONSTIPATION			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
DENTAL CARIES			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DIARRHOEA			
subjects affected / exposed	3 / 3 (100.00%)	2 / 3 (66.67%)	3 / 4 (75.00%)
occurrences (all)	15	8	6
DRY MOUTH			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DYSPEPSIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
DYSPHAGIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
FLATULENCE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
FREQUENT BOWEL MOVEMENTS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GINGIVAL BLEEDING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MOUTH ULCERATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
subjects affected / exposed	2 / 3 (66.67%)	3 / 3 (100.00%)	2 / 4 (50.00%)
occurrences (all)	8	6	6

NONINFECTIVE GINGIVITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ORAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RECTAL FISSURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
RECTAL POLYP			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
STOMATITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TONGUE ULCERATION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
TOOTHACHE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VOMITING			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	2 / 4 (50.00%)
occurrences (all)	2	9	3
Hepatobiliary disorders			
HYPERBILIRUBINAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
ACTINIC KERATOSIS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ALOPECIA			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD BLISTER			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
COLD SWEAT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
DERMATOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DRY SKIN			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
ERYTHEMA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
NIGHT SWEATS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
RASH			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
RASH VESICULAR			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
SKIN DISCOLOURATION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
SKIN LESION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
URTICARIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			

DYSURIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HAEMATURIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NOCTURIA			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
POLLAKIURIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RENAL CYST			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RENAL PAIN			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
AUTOIMMUNE HYPOTHYROIDISM			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
BACK PAIN			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1
BONE PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DUPUYTREN'S CONTRACTURE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
GROIN PAIN			

subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
JOINT SWELLING			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 4 (0.00%)
occurrences (all)	0	3	0
LIMB DISCOMFORT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
MUSCLE SPASMS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL DISCOMFORT			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OSTEITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OSTEOPENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
OSTEOPOROSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			

ACUTE SINUSITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BRONCHITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CELLULITIS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
CONJUNCTIVITIS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
ESCHERICHIA INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EYE INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
GASTROENTERITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HAEMOPHILUS INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HERPES SIMPLEX			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 4 (50.00%)
occurrences (all)	1	2	3
HERPES ZOSTER			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
LICE INFESTATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LOCALISED INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
NASOPHARYNGITIS			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)
occurrences (all)	2	4	1
ORAL CANDIDIASIS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ORAL HERPES			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
OTITIS MEDIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PARONYCHIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA KLEBSIELLA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RESPIRATORY TRACT INFECTION VIRAL			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
RHINITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RHINOVIRUS INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
SINUSITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
SKIN INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
STAPHYLOCOCCAL INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TOOTH ABSCESS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 4 (50.00%)
occurrences (all)	1	6	2
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	0 / 4 (0.00%)
occurrences (all)	1	3	0
VASCULAR DEVICE INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VIRAL INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	1 / 4 (25.00%)
occurrences (all)	1	3	1
VULVOVAGINAL CANDIDIASIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 4 (50.00%)
occurrences (all)	2	1	2
DEHYDRATION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
HYPERGLYCAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPERPHOSPHATAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPERURICAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
HYPOVOLAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VITAMIN D DEFICIENCY			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Navitoclax 21/21 Day Cycle: 250 mg	Navitoclax 21/21 Day Cycle: 300 mg	Phase 2: Navitoclax 100 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	4 / 4 (100.00%)	4 / 4 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 4 (25.00%)
occurrences (all)	0	2	1
COLORECTAL ADENOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SKIN PAPILLOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HAEMATOMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPERTENSION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HYPOTENSION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VASCULITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ADVERSE DRUG REACTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ASTHENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CHEST DISCOMFORT			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CHEST PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FATIGUE			
subjects affected / exposed	2 / 3 (66.67%)	1 / 4 (25.00%)	1 / 4 (25.00%)
occurrences (all)	2	1	2
FEELING HOT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GAIT DISTURBANCE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
OEDEMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
PAIN			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
SECRETION DISCHARGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VESSEL PUNCTURE SITE PAIN			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Immune system disorders ALLERGY TO ARTHROPOD BITE subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
SEASONAL ALLERGY subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 4 (0.00%) 0
Reproductive system and breast disorders BENIGN PROSTATIC HYPERPLASIA subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
ERECTILE DYSFUNCTION subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
PENILE CURVATURE subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
PROSTATITIS subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Respiratory, thoracic and mediastinal disorders ASTHMA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
COUGH subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	0 / 4 (0.00%) 0	1 / 4 (25.00%) 1
DYSPNOEA subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
EPISTAXIS subjects affected / exposed occurrences (all)	2 / 3 (66.67%) 7	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
HAEMOPTYSIS			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HAEMOTHORAX			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 4 (50.00%)
occurrences (all)	0	0	2
PRODUCTIVE COUGH			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
PULMONARY OEDEMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RESPIRATORY TRACT CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SINUS CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SPUTUM DISCOLOURED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
THROAT IRRITATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
WHEEZING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
AGITATION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0

ANXIETY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
INSOMNIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	2 / 3 (66.67%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	9	0	2
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD GLUCOSE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
BLOOD MAGNESIUM DECREASED			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

HAEMOGLOBIN DECREASED subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
HEART RATE IRREGULAR subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
LIPASE INCREASED subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
WEIGHT DECREASED subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 4 (25.00%) 2	0 / 4 (0.00%) 0
WEIGHT INCREASED subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Injury, poisoning and procedural complications			
CONTUSION subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
FALL subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
HUMERUS FRACTURE subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
LIGAMENT SPRAIN subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
MENISCUS INJURY subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
PROCEDURAL PAIN subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
SKIN ABRASION			

subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
SKIN LACERATION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
SUNBURN			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
WOUND			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
PHIMOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
ANGINA PECTORIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BRADYCARDIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CARDIAC FAILURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VENTRICULAR EXTRASYSTOLES			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
APHASIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DIZZINESS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	3	0
DYSGEUSIA			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HEADACHE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
LETHARGY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NEUROPATHY PERIPHERAL			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SENSORY DISTURBANCE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TASTE DISORDER			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
LYMPHADENOPATHY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NEUTROPENIA			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	5	0
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 4 (25.00%)
occurrences (all)	0	3	2
Ear and labyrinth disorders			
EAR CONGESTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EAR DISCOMFORT			

subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
EAR PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CONJUNCTIVAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
DACRYOSTENOSIS ACQUIRED			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ECTROPION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EYE HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RETINAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
SWELLING OF EYELID			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 4 (50.00%)
occurrences (all)	0	0	2
ABDOMINAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	3
ABDOMINAL PAIN UPPER			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
DENTAL CARIES			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DIARRHOEA			
subjects affected / exposed	3 / 3 (100.00%)	3 / 4 (75.00%)	4 / 4 (100.00%)
occurrences (all)	10	8	5
DRY MOUTH			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DYSPEPSIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
DYSPHAGIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FLATULENCE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
FREQUENT BOWEL MOVEMENTS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GINGIVAL BLEEDING			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
MOUTH ULCERATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

NAUSEA			
subjects affected / exposed	2 / 3 (66.67%)	2 / 4 (50.00%)	2 / 4 (50.00%)
occurrences (all)	2	2	2
NONINFECTIVE GINGIVITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ORAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
RECTAL FISSURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
RECTAL POLYP			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
STOMATITIS			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
TONGUE ULCERATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TOOTHACHE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VOMITING			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	1 / 4 (25.00%)
occurrences (all)	2	1	1
Hepatobiliary disorders			
HYPERBILIRUBINAEMIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			

ACTINIC KERATOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ALOPECIA			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
BLOOD BLISTER			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
COLD SWEAT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DERMATOSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DRY SKIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ERYTHEMA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NIGHT SWEATS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
RASH			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
RASH VESICULAR			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SKIN DISCOLOURATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SKIN LESION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0

URTICARIA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Renal and urinary disorders			
DYSURIA subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
HAEMATURIA subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
NOCTURIA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
POLLAKIURIA subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
RENAL CYST subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
RENAL PAIN subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Endocrine disorders			
AUTOIMMUNE HYPOTHYROIDISM subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
BACK PAIN subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 4 (25.00%) 1	0 / 4 (0.00%) 0
BONE PAIN subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 4 (0.00%) 0

DUPUYTREN'S CONTRACTURE			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GROIN PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LIMB DISCOMFORT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL DISCOMFORT			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
NECK PAIN			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
OSTEITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OSTEOPENIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OSTEOPOROSIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

PAIN IN EXTREMITY			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
ACUTE SINUSITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BRONCHITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CELLULITIS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
CONJUNCTIVITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ESCHERICHIA INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
EYE INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HAEMOPHILUS INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HERPES SIMPLEX			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HERPES ZOSTER			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LICE INFESTATION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LOCALISED INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	3	0	1
ORAL CANDIDIASIS			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
ORAL HERPES			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
OTITIS MEDIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PARONYCHIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA KLEBSIELLA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0

RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RHINITIS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RHINOVIRUS INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SINUSITIS			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
SKIN INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
STAPHYLOCOCCAL INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TOOTH ABSCESS			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	1	5	0
VASCULAR DEVICE INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VIRAL INFECTION			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL CANDIDIASIS			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 4 (25.00%)
occurrences (all)	0	2	1
DEHYDRATION			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HYPERPHOSPHATAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
HYPERURICAEMIA			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HYPOKALAEMIA			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	1	2	0
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
HYPOVOLAEMIA			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
VITAMIN D DEFICIENCY			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase 2: Navitoclax 250 mg		
Total subjects affected by non-serious adverse events			

subjects affected / exposed	27 / 27 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BASAL CELL CARCINOMA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
COLORECTAL ADENOMA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
SKIN PAPILLOMA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HAEMATOMA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
HYPERTENSION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
HYPOTENSION			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
VASCULITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
ADVERSE DRUG REACTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ASTHENIA			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
CHEST DISCOMFORT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
CHEST PAIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
FATIGUE			
subjects affected / exposed	10 / 27 (37.04%)		
occurrences (all)	14		
FEELING HOT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
GAIT DISTURBANCE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
OEDEMA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
OEDEMA PERIPHERAL			
subjects affected / exposed	7 / 27 (25.93%)		
occurrences (all)	7		
PAIN			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	2		
PERIPHERAL SWELLING			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
PYREXIA			
subjects affected / exposed	4 / 27 (14.81%)		
occurrences (all)	5		
SECRETION DISCHARGE			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>VESSEL PUNCTURE SITE PAIN</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p>		
<p>Immune system disorders</p> <p>ALLERGY TO ARTHROPOD BITE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SEASONAL ALLERGY</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>1</p>		
<p>Reproductive system and breast disorders</p> <p>BENIGN PROSTATIC HYPERPLASIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ERECTILE DYSFUNCTION</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PENILE CURVATURE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PROSTATITIS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>2</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>ASTHMA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>COUGH</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>DYSPNOEA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>EPISTAXIS</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>6 / 27 (22.22%)</p> <p>7</p> <p>1 / 27 (3.70%)</p> <p>1</p>		

subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	5		
HAEMOPTYSIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HAEMOTHORAX			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
NASAL CONGESTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
OROPHARYNGEAL PAIN			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
PRODUCTIVE COUGH			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
PULMONARY OEDEMA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RESPIRATORY TRACT CONGESTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
SINUS CONGESTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
SPUTUM DISCOLOURED			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
THROAT IRRITATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
WHEEZING			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			

AGITATION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
ANXIETY			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
INSOMNIA			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	6		
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	3		
BLOOD CREATININE INCREASED			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
BLOOD GLUCOSE INCREASED			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
BLOOD MAGNESIUM DECREASED			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

<p>GAMMA-GLUTAMYLTRANSFERASE INCREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HAEMOGLOBIN DECREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HEART RATE IRREGULAR</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>LIPASE INCREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WEIGHT DECREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WEIGHT INCREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>2 / 27 (7.41%)</p> <p>5</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>3 / 27 (11.11%)</p> <p>3</p> <p>1 / 27 (3.70%)</p> <p>1</p>		
<p>Injury, poisoning and procedural complications</p> <p>CONTUSION</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FALL</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HUMERUS FRACTURE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>LIGAMENT SPRAIN</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>MENISCUS INJURY</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PROCEDURAL PAIN</p>	<p>3 / 27 (11.11%)</p> <p>3</p> <p>2 / 27 (7.41%)</p> <p>2</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p>		

<p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>SKIN ABRASION</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>SKIN LACERATION</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>SUNBURN</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>WOUND</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Congenital, familial and genetic disorders</p> <p>PHIMOSIS</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Cardiac disorders</p> <p>ANGINA PECTORIS</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>BRADYCARDIA</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>CARDIAC FAILURE</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>VENTRICULAR EXTRASYSTOLES</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Nervous system disorders</p> <p>APHASIA</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>DIZZINESS</p>			

subjects affected / exposed	4 / 27 (14.81%)		
occurrences (all)	4		
DYSGEUSIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
HEADACHE			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	4		
LETHARGY			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
NEUROPATHY PERIPHERAL			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
SENSORY DISTURBANCE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
TASTE DISORDER			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	4 / 27 (14.81%)		
occurrences (all)	7		
LYMPHADENOPATHY			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
NEUTROPENIA			
subjects affected / exposed	7 / 27 (25.93%)		
occurrences (all)	20		
THROMBOCYTOPENIA			
subjects affected / exposed	13 / 27 (48.15%)		
occurrences (all)	39		
Ear and labyrinth disorders			
EAR CONGESTION			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
EAR DISCOMFORT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
EAR PAIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
CONJUNCTIVAL HAEMORRHAGE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
DACRYOSTENOSIS ACQUIRED			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ECTROPION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
EYE HAEMORRHAGE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RETINAL HAEMORRHAGE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
SWELLING OF EYELID			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	6		
ABDOMINAL PAIN			

subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	3		
ABDOMINAL PAIN UPPER			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
CONSTIPATION			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
DENTAL CARIES			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
DIARRHOEA			
subjects affected / exposed	20 / 27 (74.07%)		
occurrences (all)	30		
DRY MOUTH			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
DYSPEPSIA			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	6		
DYSPHAGIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
FLATULENCE			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
FREQUENT BOWEL MOVEMENTS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
GINGIVAL BLEEDING			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		

MOUTH ULCERATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
NAUSEA			
subjects affected / exposed	13 / 27 (48.15%)		
occurrences (all)	17		
NONINFECTIVE GINGIVITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ORAL PAIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RECTAL FISSURE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RECTAL POLYP			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
STOMATITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
TONGUE ULCERATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
TOOTHACHE			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
VOMITING			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	5		
Hepatobiliary disorders			
HYPERBILIRUBINAEMIA			

subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	4		
Skin and subcutaneous tissue disorders			
ACTINIC KERATOSIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ALOPECIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
BLOOD BLISTER			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
COLD SWEAT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
DERMATOSIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
DRY SKIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ERYTHEMA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
NIGHT SWEATS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
RASH			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
RASH VESICULAR			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
SKIN DISCOLOURATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

SKIN LESION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
URTICARIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
DYSURIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
HAEMATURIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
NOCTURIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
POLLAKIURIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RENAL CYST			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RENAL PAIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Endocrine disorders			
AUTOIMMUNE HYPOTHYROIDISM			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	5		
BACK PAIN			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	4		

BONE PAIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
DUPUYTREN'S CONTRACTURE			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
GROIN PAIN			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
JOINT SWELLING			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
LIMB DISCOMFORT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
MUSCLE SPASMS			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
MUSCULOSKELETAL DISCOMFORT			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
MUSCULOSKELETAL PAIN			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
MYALGIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
NECK PAIN			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
OSTEITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
OSTEOPENIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

OSTEOPOROSIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
PAIN IN EXTREMITY			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	5		
Infections and infestations			
ACUTE SINUSITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
BRONCHITIS			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	5		
CELLULITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
CONJUNCTIVITIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
ESCHERICHIA INFECTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
EYE INFECTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
GASTROENTERITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HAEMOPHILUS INFECTION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
HERPES SIMPLEX			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HERPES ZOSTER			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
INFLUENZA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
LICE INFESTATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
LOCALISED INFECTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	5		
NASOPHARYNGITIS			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	7		
ORAL CANDIDIASIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
ORAL HERPES			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
OTITIS MEDIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
PARONYCHIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
PNEUMONIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

PNEUMONIA KLEBSIELLA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RHINITIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
RHINOVIRUS INFECTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
SINUSITIS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
SKIN INFECTION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
STAPHYLOCOCCAL INFECTION			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
TOOTH ABSCESS			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	8 / 27 (29.63%)		
occurrences (all)	11		
URINARY TRACT INFECTION			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	10		
VASCULAR DEVICE INFECTION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
VIRAL INFECTION			

subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
VULVOVAGINAL CANDIDIASIS			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	8 / 27 (29.63%)		
occurrences (all)	10		
DEHYDRATION			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	3		
HYPERPHOSPHATAEMIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HYPERURICAEMIA			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	5		
HYPOKALAEMIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
HYPOVOLAEMIA			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
TUMOUR LYSIS SYNDROME			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
VITAMIN D DEFICIENCY			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 December 2010	<ul style="list-style-type: none">• Added the ABT-263 Meltrex® tablet formulation (once available) in Section 5.5 (Treatments).• Removed the option to supply ABT-263 stabilized solution in bottles (i.e., it must be provided in prefilled syringes) in Section 5.5 (Treatments).• Changed the requirement for ABT-263 to be administered within 30 minutes after the completion of breakfast throughout the protocol to ensure that ABT-263 is taken closer to the time of a meal, as the Meltrex® tablet formulation is known to have a food effect.• In Section 5.3.2.1 (Collection of Samples for Analysis), added the requirement to record the date and time of doses and whether or not doses were taken within 30 minutes of completing breakfast for the pre-dose (0 hour) PK sampling day and for the two days prior to each PK sampling day. These changes were made due to the known food effect of the Meltrex® formulation.• Added (Cycle/Day) abbreviations to column header in Table 3 Schedule of Assessments.• Retitled Table 6 to better indicate that it pertains to the Phase 2a, 21/21 Day Continuous Dosing Schedule.• Added a reference to Table 5 for pharmacokinetic sampling timepoints during Cycle 1 of the Phase 1 - 14/21 Day Dosing Schedule in Section 5.3.1.1 (Study Procedures).• Changed the shipping contact, e-mail and address for the Bcl-2/Bim Ratio samples in Section 5.3.1.4 (Specimen for Pharmacodynamic Analyses).• Added that if a follow-up visit is not performed, the reason should be noted in the subject's source documentation in Section 5.4.1 (Discontinuation of Individual Subjects).• Clarified that a designee for the site pharmacist may prepare and dispense prefilled stabilized solution syringes in Section 5.5.2 (Identity of Investigational Product).• Added Adapt-a-Caps for bottles of oral solution to the list of ancillary materials supplied by Abbott in Section 5.5.2 (Identity of Investigational Product).• Retitled Table 6 to better indicate that it pertains to the Phase 2a, 21/21 Day Schedule.
01 December 2010	<p>(continued)</p> <ul style="list-style-type: none">• Clarified that empty bottles of study drug will be destroyed at the site in Section 5.5.7 (Drug Accountability).• Removed "Hospitalization" as a stand alone criterion in Section 6.1.2 (Serious Adverse Events) as it is already covered under the "Hospitalization or Prolongation of Hospitalization" criterion.• Added cellular phone number for the Abbott Medical Monitor in Section 1.0 (Title Page) and Section 7.0 (Protocol Deviations) and corrected it in Section 6.5 (Adverse Event Reporting).• Updated Sponsor contact information in Section 7.0 (Protocol Deviations).• Updated Appendix B to reflect current protocol signatories.• Corrected typographical errors.

11 May 2011	<ul style="list-style-type: none"> • Developed an Extension Study to allow subjects who remain active to continue receiving ABT-263 with less frequent study evaluations. Subjects in the Extension Study may continue to receive study drug for up to three years after the last subject transitions to the Extension Study. • Updated Section 3.0 (Introduction) in order to align with current toxicology findings for ABT-263. • Updated Section 5.3.1.3 (Blood Samples for Pharmacogenetic Analyses), Section 5.3.1.4 (Specimens for Pharmacodynamic Analyses) and Section 5.3.2.2 (Handling/Processing of Samples) to remove processing and shipping instructions. Added reference to the M06-873 Laboratory Manual to allow for revisions to be made to the Laboratory Manual without the need to amend the protocol. • Updated Section 5.3.2.3 (Disposition of Samples for ABT-263 Assay) to include sample labeling instructions. • Revised Section 5.5.2 (Identity of Investigational Product) to remove the option of ABT-263 Powder for Oral Solution, which will no longer be available in the future. • Clarified in Section 5.5.7 (Drug Accountability) that empty study drug bottles will be destroyed per the site's destruction policy, if applicable. • Clarified in Section 6.2 (Adverse Event Severity) that if an adverse event increases in severity, a new adverse event should be reported. • Revised Appendix E to reflect the current sample list of excluded and cautionary medications for ABT-263. • Added changes previously noted in Administrative Change 3 (09 Dec 2010). • Updated Sponsor contact information in Section 7.0 (Protocol Deviations). • Updated Appendix B to reflect current protocol signatories. • Format changes to Appendix F to reflect Abbott standards. • Corrected typographical errors.
08 August 2016	<ul style="list-style-type: none"> • Extend the duration of the Extension Phase from 5 years to 7 years after the last subject transitions. • Update the contact information for AbbVie contacts. • Update Section 3.0, Introduction • Clarify Section 5.3.1.1, Study Procedures. • Update Section 6.5, Adverse Event Reporting, to include 24 hour emergency contact phone number. • Update Section 5.3.1.4, Specimens for Pharmacodynamic Analyses, the biomarkers ZAP70/CD38 (US sites only), the CGH/FISH (AUS sites only) and Bcl-2/Bim Ratio (US and AUS sites) blood collections have been removed from the Final Visit for subjects in the Extension Study. • Updated Section 15.0, Reference List. • Update Appendix B, List of Protocol Signatories. • Update Appendix D, Responsibilities of the Clinical Investigator. • Incorporate additional administrative changes.
26 July 2018	<ul style="list-style-type: none"> • Extend the duration of the Extension Phase from 7 years to 9 years after the last subject transitions. • Update the contact information for AbbVie contacts in Section 1.0, Title Page, Section 6.5, Adverse Event Reporting, and Section 7.0 Protocol Deviation. • Update Section 5.3.1.4 and update of Table 9 and Appendix G, Table 1 and Table 2. Remove the Biomarker Sample Collection (Phase 2a), at the Final Visit for subjects enrolled in the Extension under this amendment. • Update Section 5.3.1. Remove the Survival follow up assessment at the 3 monthly intervals after study discontinuation, unless a very small number of patients are available for overall survival (OS) follow-up. • Updated Section 15.0, Reference List. • Update Appendix B, List of Protocol Signatories. • Make minor language or word revisions throughout the document. • Incorporate additional administrative changes.

29 January 2020	<ul style="list-style-type: none"> • Extend the duration of the Extension Phase from 9 years to 11 years after the last subject transitions. • Update the contact information for AbbVie contacts in Section 1.0, Title Page, Section 6.5, Adverse Event Reporting, and Section 7.0 Protocol Deviation. • Updated Section 15.0, Reference List. • Update Appendix B, List of Protocol Signatories. • Updated Appendix G, Table 1 (Extension Study: Schedule of Assessments) to delete the post-treatment and biomarker sample collection information • Deleted Table 2, (Extension Study: Schedule of Biomarker Sample Collection) • Remove PK sample collections from subjects enrolled into the Extension Study. • Remove reference to central lab.
03 September 2020	<ul style="list-style-type: none"> • Section 3.0 – Included information on the re-evaluation of the benefit and risk to subjects participating in the study. • Section 5.4.1 – Added that the investigator should contact the sponsor medical contact before discontinuing a subject from the study for a reason other than "planned per protocol." • Section 5.5.1 – Added delays in study drug dosing due to the above COVID-19 testing guidance. • Section 5.5.4 – Included instructions that in the event the subject cannot pick up study drug onsite, DTP (Direct To Patient) shipment can be made, as permitted by local regulations. • Section 7.0 – clarified that protocol deviations may include modifications due to COVID-19. • Section 9.1 – Added that AbbVie will modify the study protocol as necessary due to the pandemic. Investigators must also notify AbbVie if any urgent safety measures are taken. • Section 10.1 – Added that remote monitoring may be employed as needed. • Appendix A – Addition of COVID-19 and DTP to list of abbreviations. • In addition, sponsor contact information updates have been made.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported